Nomelcitinib Hits Primary Endpoint in Phase 3 Psoriasis Trial

InventisBio Co.’s nomelcitinib (D-2570) met the primary endpoint and the key secondary endpoint in a registrational Phase 3 clinical trial for moderate-to-severe plaque psoriasis.

InventisBio Co.’s nomelcitinib (D-2570) met the primary endpoint and the key secondary endpoint in a registrational Phase 3 clinical trial for moderate-to-severe plaque psoriasis.